Home/Pipeline/SPY230

SPY230

Ulcerative Colitis

Phase 1Active

Key Facts

Indication

Ulcerative Colitis

Phase

Phase 1

Status

Active

Company

Spyre Therapeutics

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotech focused on redefining treatment for inflammatory bowel disease (IBD) and rheumatological conditions by engineering monoclonal antibodies with dramatically extended half-lives. The company's core strategy is to reduce the burden of frequent dosing, aiming for quarterly or twice-annual administration, while targeting validated pathways like α4β7, TL1A, and IL-23. With a multi-asset pipeline centered on the Phase 2 SKYLINE-UC trial and key data readouts expected throughout 2026, Spyre is positioning itself as a potential leader in next-generation, high-convenience biologic therapies.

View full company profile

Therapeutic Areas

Inflammatory Bowel Disease Rheumatology

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
BB265	BiomeBank	Phase 1	Active
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active